First-in-human study of neuron regenerative therapy NNI-362 to evaluate the safety, pharmacokinetics, and pharmacodynamics in healthy aged population.

Alzheimers Res Ther · 2025 · PMC12330068 · PMID 40775373

Europe PMC DOI

hedged sentence

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

showed a trendP = 0.08so close (0.05 < p ≤ 0.1)

Whereas the two active arms showed no difference at Day 16 on mean change from baseline, the high dose showed a trend toward a faster decline than the lower dose at Day 15 ( P = 0.08).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.